Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study
September 01 2021 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody-drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced plans to host a
live conference call and webcast on Friday, September 10, 2021 at
8:00 a.m. ET to discuss the progress of its clinical development
strategy for upifitamab rilsodotin (UpRi) and report updated
interim data from the ovarian cancer expansion cohort of the UpRi
Phase 1 study. Enrollment in the expansion cohort is complete with
97 patients evaluable for safety and tolerability, of which 75 are
RECIST-evaluable at this interim analysis.
Members of the Mersana executive team will be
joined by lead investigator, Debra L. Richardson, MD Associate
Professor and Section Chief of Gynecologic Oncology at the
Stephenson Cancer Center at the University of Oklahoma Health
Sciences Center and the Sarah Cannon Research Institute.
Conference Call DetailsTo
access the call, please dial 877-303-9226 (domestic) or
409-981-0870 (international) and provide the Conference ID 1441618.
A live webcast of the presentation will be available on the
Investors & Media section of the Mersana website at
www.mersana.com.
About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms to rapidly develop novel ADCs with optimal efficacy,
safety and tolerability to meaningfully improve the lives of people
fighting cancer. Mersana’s lead product candidate, upifitamab
rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is
being studied in UPLIFT, a single-arm registration strategy in
patients with platinum-resistant ovarian cancer, as well as in
UPGRADE, a Phase 1 umbrella study in combination with other ovarian
cancer therapies. UpRi is also being studied in the expansion
portion of a Phase 1 proof-of-concept clinical study. XMT-1592,
Mersana’s second ADC product candidate targeting NaPi2b-expressing
tumors, was created using Mersana’s customizable and homogeneous
Dolasynthen platform and is in the dose escalation portion of a
Phase 1 proof-of-concept clinical study. The Company’s early-stage
programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as
well as XMT-2056, a STING-agonist ADC developed using the Company’s
Immunosynthen platform. In addition, multiple partners are using
Mersana’s Dolaflexin platform to advance their ADC pipelines. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Forward-Looking StatementsThis
press release contains “forward-looking” statements within the
meaning of federal securities laws. These forward-looking
statements are not statements of historical facts and are based on
management’s beliefs and assumptions and on information currently
available to management. Forward-looking statements include
information concerning the Company’s clinical strategy for its
product candidates, progression and timing of its clinical study
and release of data from its clinical study, the ability of the
single-arm UPLIFT cohort to enable registration, and expectations
regarding future clinical trial results. Forward-looking statements
generally can be identified by terms such as “aims,” “anticipates,”
“believes,” “contemplates,” “continues,” “could,” “estimates,”
“expects,” “goal,” “intends,” “may,” “on track,” “opportunity,”
“plans,” “poised for,” “possible,” “potential,” “predicts,”
“projects,” “promises to be,” “seeks,” “should,” “target,” “will,”
“would” or similar expressions and the negatives of those terms.
Forward-looking statements represent management’s beliefs and
assumptions only as of the date of this press release. The
Company’s operations involve risks and uncertainties, many of which
are outside its control, and any one of which, or combination of
which, could materially affect its results of operations and
whether the forward-looking statements ultimately prove to be
correct. Factors that may materially affect the Company’s results
of operations and whether these forward-looking statements prove to
be correct include, among other things, that preclinical testing or
early clinical results may not be predictive of the results or
success of ongoing or later preclinical or clinical studies, that
results of the Company’s ongoing or future clinical studies may be
inconclusive with respect to the efficacy of the Company’s product
candidates, that the Company may not meet clinical endpoints with
statistical significance or there may be safety concerns or adverse
events associated with product candidates, that the identification,
development and testing of the Company’s product candidates and new
platforms will take longer and/or cost more than planned, and that
the Company’s clinical studies may not be initiated or completed on
schedule, if at all, as well as those listed in the Company’s
Quarterly Report on Form 10-Q filed on August 6, 2021, with the
Securities and Exchange Commission (“SEC”), and subsequent SEC
filings. In addition, while we expect that the COVID-19 pandemic
may adversely affect the Company’s preclinical and clinical
development efforts, business operations and financial results, the
extent of the impact on the Company’s operations and the value of
and market for the Company’s common stock will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, the spread of variants of COVID-19, including the Delta
variant, travel restrictions, quarantines, physical distancing and
business closure requirements in the U.S. and in other countries,
and the effectiveness of actions taken globally to contain and
treat the disease. Except as required by law, the Company assumes
no obligation to update these forward-looking statements publicly,
or to update the reasons actual results could differ materially
from those anticipated in the forward-looking statements, even if
new information becomes available in the future.
Contact:
Investor & Media ContactSarah Carmody,
617-844-8577scarmody@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024